We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Moxonidine in Indian Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00160277
First Posted: September 12, 2005
Last Update Posted: January 30, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Solvay Pharmaceuticals
September 9, 2005
September 12, 2005
January 30, 2009
July 2005
Not Provided
Systolic blood pressure reduction
Not Provided
Complete list of historical versions of study NCT00160277 on ClinicalTrials.gov Archive Site
Piggy-back pharmacoeconomic evaluation; Safety and tolerability
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of Moxonidine in Indian Patients
Open Label, Multi-Center, Force-Titration Study to Evaluate the Efficacy and Safety of Moxonidine in Ambulatory Subjects With Essential Hypertension
The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hypertension
Drug: Moxonidine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Not Provided
Not Provided

Inclusion Criteria:

Hypertension

Exclusion Criteria:

Severe concomitant diseases, CHF, secondary hypertension, severe hypertension, significant hepatic disease, unstable angina

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
India
 
 
NCT00160277
S220.3.124
Not Provided
Not Provided
Not Provided
Not Provided
Solvay Pharmaceuticals
Not Provided
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
Solvay Pharmaceuticals
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP